Titre:
  • Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
Auteur:Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, Vernon; Thürlimann, Beat; Cardoso, Fatima; Pagani, Olivia; Coates, Alan; Goldhirsch, Aron; Price, Karen N.; Gelber, R D; Bernhard, Jürg; BIG 1-98 Collaborative and International Breast Cancer Study Groups, ; International Breast Cancer Study Group,
Informations sur la publication:British Journal of Cancer, 106, 10, page (1618-1625)
Statut de publication:Publié, 2012-05
Sujet CREF:Cancérologie
Mots-clés:Aromatase inhibitor
Breast cancer
Letrozole
Quality of life
Subjective cognitive function
Tamoxifen
MeSH keywords:Aromatase Inhibitors -- adverse effects
Breast Neoplasms -- drug therapy -- pathology -- psychology
Cognition -- drug effects
Estrogen Antagonists -- adverse effects
Female
Humans
Neoplasm Staging
Nitriles -- adverse effects
Quality of Life
Tamoxifen -- adverse effects
Triazoles -- adverse effects
Note générale:Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0007-0920
info:doi/10.1038/bjc.2012.156
info:pii/bjc2012156
info:scp/84860779907
info:pmid/22531635
PMC3349183